Orthopedics, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
BMJ Case Rep. 2022 May 12;15(5):e248837. doi: 10.1136/bcr-2022-248837.
There is a controversy over the medical treatment of unresectable spinal giant cell tumour (GCT) regarding dosing and duration. We studied a spinal GCT case that had expanded to the thoracic spinal canal and mediastinum and was successfully treated by surgical decompression and denosumab. A woman in her 30s presented with weakness in both the lower extremities. MRI revealed a large tumour in the posterior mediastinum expanding from the thoracic vertebrae (T3-6), which compressed the spinal cord. The patient underwent urgent spinal decompression with instrumentation and her tissue was sent for a pathology study. Histologically and immunohistochemistry confirmed the diagnosis of GCT. Since it was an unresectable tumour, this patient was treated with denosumab. Her neurological problem resolved after 6 months of treatment. After 4 years of follow-up, the patient displayed no further progression and no side effects from long-term denosumab usage.
对于无法切除的脊柱巨细胞瘤(GCT)的治疗剂量和持续时间存在争议。我们研究了一例脊柱 GCT 病例,该病例已扩展到胸椎管和纵隔,并通过手术减压和地舒单抗成功治疗。一位 30 多岁的女性出现下肢无力。MRI 显示后纵隔有一个大肿瘤,从胸椎(T3-6)扩展,压迫脊髓。患者接受了紧急脊柱减压和器械固定,其组织被送去进行病理研究。组织学和免疫组织化学证实了 GCT 的诊断。由于这是一个无法切除的肿瘤,该患者接受了地舒单抗治疗。治疗 6 个月后,她的神经问题得到解决。4 年后随访,患者无进一步进展,长期使用地舒单抗无副作用。